SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Wernroth Lisa)
 

Sökning: WFRF:(Wernroth Lisa) > Fibrinolytic therap...

Fibrinolytic therapy and bleeding complications: risk predictors from RIKS-HIA

Oldgren, Jonas (författare)
Uppsala universitet,Uppsala kliniska forskningscentrum (UCR)
Wernroth, Lisa (författare)
Uppsala universitet,Uppsala kliniska forskningscentrum (UCR)
Stenestrand, Ulf (författare)
Östergötlands Läns Landsting,Linköpings universitet,Kardiologi,Hälsouniversitetet,Kardiologiska kliniken
 (creator_code:org_t)
2010-07-23
2010
Engelska.
Ingår i: HEART. - : BMJ Publishing Group; 1999. - 1355-6037 .- 1468-201X. ; 96:18, s. 1451-1457
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Background Fibrinolytic treatment for ST-elevation myocardial infarction is associated with increased bleeding risk but is still widely used world wide, mainly because of limited access to primary PCI. Objective To analyse contemporary fibrinolytic treatment patterns, in-hospital bleeding risk and prognosis during 2001 to 2006 in unselected Swedish patients. Methods and results The RIKS-HIA registry covers almost all Swedish patients treated for acute coronary syndromes. Major in-hospital bleeding was defined as lethal or intracranial bleeding or bleeding requiring surgery or blood transfusion. Survival status of the 15 373 patients was obtained from the National Cause of Death Register. The number of patients receiving fibrinolysis as reperfusion therapy decreased from 4336 patients in 2001 to 733 in 2006. Cases of major in-hospital bleeding increased from 1.2% (including 0.7% lethal or intracranial) in 2001 to 4.0% (1.1%) in 2006, pandlt;0.001. Higher age, female gender, hypertension, kidney failure, clopidogrel treatment before admission, pre-hospital administration of fibrinolysis and fibrin-specific fibrinolytic agents were identified as predictors for bleeding. Major in-hospital bleeding was the strongest predictor of adverse prognosis with a more than threefold increase in 1-year mortality. Conclusion During 2001 to 2006 the use of fibrinolytic treatment markedly decreased while the incidence of major bleeding complications more than doubled. The latter might in part be explained by increasing use concomitant antiplatelet therapy, pre-hospital treatment and fibrin-specific fibrinolytic agents. Future close monitoring of bleeding complications is warranted, especially when considering the increased use of various combinations of antithrombotic drugs in conjunction with fibrinolysis and the great impact of bleeding on long-term mortality.

Nyckelord

MEDICINE
MEDICIN

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

  • HEART (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Hitta mer i SwePub

Av författaren/redakt...
Oldgren, Jonas
Wernroth, Lisa
Stenestrand, Ulf
Artiklar i publikationen
HEART
Av lärosätet
Linköpings universitet
Uppsala universitet

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy